@FierceBiotech: From FierceBiomarkers.com : Brain scan may provide biomarker guideposts to ideal depression treatment. Article | Follow @FierceBiotech
@JohnCFierce: Look for early competition on hep C: Gilead 1, AbbVie in photo finish 2; BMS 3. As ranked by Bloomberg. Report | Follow @JohnCFierce
@RyanMFierce: AbbVie: We can beat Gilead in blockbuster hep C race. Report | Follow @RyanMFierce
> After a meeting with the FDA, Cempra ($CEMP) updated investors on its expected clinical trials strategy for Phase III development of its lead antibiotic solithromycin for community-acquired bacterial pneumonia. It's raising funding to pay for the work. Item
> The Street's Adam Feuerstein took a hard look at lab data that bolster his case for why Vertex Pharmaceuticals ($VRTX) have a $10 billion franchise with combination cystic fibrosis treatments. Column
> Bristol-Myers Squibb ($BMY) and Simcere Pharmaceutical Group ($SCR) have expanded their 2010 pact with an agreement to join forces on development of BMS' Orencia for rheumatoid arthritis in China. Release
> CoMentis and Anvyl formed a joint venture called Alpharmagen to study nicotinic modulators, a class of drug that has shown promise in midstage studies for patients with Alzheimer's disease. Release
@FiercePharma: Come join our new LinkedIn group to connect with others in the industry and read, share and discuss the latest news. Join the group | Follow @FiercePharma
@EricPFierce: FDA approves Amgen's Xgeva for bone tumor. It is a small market for a key drug that is not yet a blockbuster. Press release | Follow @EricPFierce
@CarlyHFierce: Gleevec patent battle between Novartis and Sun Pharma moving to the U.S. Yesterday's story | Follow @CarlyHFierce
> AbbVie says it could beat Gilead to huge market for hep C drugs. More
> Wockhardt gets kicked in the gut again. Report
> Pfizer's potential stars Eliquis, Xeljanz see sluggish sales. Story
@FierceMedDev: MC10 pushes wearable sensors with Medtronic co-sign. News | Follow @FierceMedDev
@DamianFierce: ICYMI: Startup NeuroTronik raised $13.1M to develop a neuromodulation solution for heart failure. News | Follow @DamianFierce
@MarkHFierce: Nearly $10M in new financing will help Veniti gain CE marking for vein treatment devices. Report | Follow @MarkHFierce
> AdvaMed to FDA: 510(k) rules are fine as they are. Story
> Japan prepares to cover cancer-related breast implants. Item
> Myriad's Supreme Court loss is Quest Diagnostics' gain. More
And Finally… Academics are calling on pharma companies to reveal details on "invisible" clinical trials that have never been reported. News